Treatment of metastatic malignant melano
β
T. Dorval; T. Palangie; M. Jouve; E. Garcia-Giralt; E. Falcoff; D. Schwab; M. Le
π
Article
π
1987
π
Springer US
π
English
β 151 KB
Twenty-six patients with histologically proven metastatic malignant melanoma were included in a phase II trial of interferon alfa-2b (Intron A; Schering-Plough). Patients were given 10 X 10(6) IU/m2 of interferon alfa-2b subcutaneously three times a week until major intolerance or progression of dis